EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of prolonged administration of corticotropin releasing factor on plasma concentrations of acth in patients with addison's disease


Experimental and Clinical Endocrinology 87(2): 208-210
Effect of prolonged administration of corticotropin releasing factor on plasma concentrations of acth in patients with addison's disease
To investigate the possibility that the prolonged administration of corticotropin releasing factor (CRF) might suppress rather than enhance pituitary ACTH-secretion 24-hour infusion (50 .mu.g/h) of ovine CRF were performed in 6 patients with adrenocortical insufficiency. CRF induced a heterogenous behavior of plasma ACTH concentrations in these hypercorticotropinemic patients but both a sustained increase and a suppression of ACTH was clearly absent at the end of the 24 hour infusion period. Thus, continuous administration of CRF does not appear to be a promising way to control abundance of plasma ACTH concentrations in patients with Addison's disease.


Accession: 005264345



Related references

Effect of prolonged administration of CRF on plasma concentrations of ACTH in patients with Addison's disease. Experimental and Clinical Endocrinology 87(2): 208-210, 1986

Acutely raised corticotropin levels in Addison's disease are not associated with increased plasma arginine vasopressin and corticotropin-releasing factor concentrations in peripheral plasma. Journal of Clinical Endocrinology and Metabolism 76(1): 192-196, 1993

Effect of synthetic ovine corticotropin releasing factor prolonged duration of action and biphasic response of plasma acth and cortisol. Journal of Clinical Endocrinology & Metabolism 57(2): 294-298, 1983

Effect of cortisol infusion on basal and corticotropin-releasing factor (CRF)-stimulated plasma ACTH concentrations in the sheep fetus after surgical isolation of the pituitary. Endocrinology 127(4): 1833-1840, 1990

Loperamide modifies but does not block the corticotropin-releasing hormone-induced ACTH response in patients with Addison's disease. Hormone and Metabolic Research. Supplement Series 16: 74-75, 1987

Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease. Neurology 37(3): 535-538, 1987

Effects of corticotropin releasing factor on plasma acth and cortisol concentrations in schizophrenia. Society for Neuroscience Abstracts 12(2): 1443, 1986

Plasma ACTH-response to the corticotropin releasing factor in patients with Cushing's disease. Comparison with the lysine-vasopressin test. Metabolism: Clinical and Experimental 33(5): 478-481, 1984

Loperamide modifies the pattern of plasma acth response to corticotropin releasing factor but not to lysine vasopressin in patients with addisons disease. 1985

Loperamide an opiate analog differently modifies the acth responses to corticotropin releasing hormone and lysine vasopressin in patients with addison's disease. Neuroendocrinology 48(6): 611-614, 1988